Q32 Bio, a US-based clinical stage biotechnology company, announced on Tuesday that it has named Saul Fink, PhD as its new chief technology officer.

In the new role, Dr Fink will be responsible for all aspects of the company's chemistry, manufacturing and control (CMC)-related activities.

Dr Fink has worked as senior vice president, Pharmaceutical and Nonclinical Development at Normunity, vice president of Pharmaceutical Development and interim lead of Nonclinical Development at Goldfinch Bio. He has served for 26 years at Bristol-Myers Squibb, partnering with executive management to define CMC strategy, drive business transformations and optimise manufacturing operations. Presently, he serves as a member of the Council of Trustees at Millersville University and as scientific advisory board member for Intrommune Therapeutics.